Nature Reviews Drug Discovery contents April 2012 Volume 11 Number 4 pp pp 251-331

Advertisement
Tecan's Spring Offer for Infinite® M1000 PRO • 10 detection modes • AlphaScreen®/AlphaLISA® • Excitation, emission, absorbance, luminescence & 3D scans • Flexible wavelength selection • Adjustable fluorescence bandwidth settings • Free definition of plate formats up to 1536-wells • Patented NanoQuant Plate™ Click here for OFFER
TABLE OF CONTENTS
April 2012 Volume 11 Number 4		Advertisement
Impact Factor 28.712 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month  Featured article: Novel molecular targets for atrial fibrillation therapy Dobromir Dobrev, Leif Carlsson & Stanley Nattel	NEW from QIAGEN: 45 pathway-reporter Cignal Dual-Luciferase Reporter Arrays. Using transfection-ready DNA Vectors or transduction-ready Lentivirus, reliably monitor the effect of drug dosages on pathway activity, uncover new pathways for orphan drugs, or discover cross-talking pathways for GPCRs/RTKs. Discover Cignal Reporter Assays at www.sabiosciences.com/ reporterassays.php
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Don't Miss Out! Deadline May 1st Are you holding the key to a research breakthrough? $3 Million in Funding now available in the following areas: • Development of therapeutics that target specific B cell lineages involved in MS pathology • Identification of surrogate or endogenous ligands for Orphan G Protein-Coupled Receptors (GPCRs) in the CNS Proposal Deadline: May 1, 2012.
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Nature Reviews Drug Discovery Poster and Video Animation on Cancer Immunotherapies This poster and video describe various immunotherapeutic strategies and antigen-specific approaches. Access the poster and video by visiting: www.nature.com/nrd/posters/cancerimmuno Produced with support from: Bavarian Nordic A/S and Dendreon
Advertisement
In this issue p251 | doi:10.1038/nrd3721 Full Text
Comment: Defining rewardable innovation in drug therapy Jeffrey K. Aronson, Robin E. Ferner & Dyfrig A. Hughes p253 | doi:10.1038/nrd3715 Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Unleashing the Mini-Sentinel Asher Mullard p255 | doi:10.1038/nrd3713 First data from the FDA's new active surveillance programme highlight how the system might influence drug development programmes. PDF
Hedgehog inhibitor gets landmark skin cancer approval, but questions remain for wider potential Malini Guha p257 | doi:10.1038/nrd3714 Approval for Genentech's vismodegib marked the first approval for a Hedgehog inhibitor, but questions remain for the class's broader role in other cancers. PDF
NEWS IN BRIEF Drug wakes latent HIV in man | Neuroscience network launches first clinical trial | Industry and academia continue to test new models of collaboration p259 | doi:10.1038/nrd3718 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q2 2012 William Akie p260 | doi:10.1038/nrd3707 PDF
BIOBUSINESS BRIEFS Deal watch: Biogen acquires Stromedix to pursue novel fibrosis therapy Sarah Crunkhorn p260 | doi:10.1038/nrd3708 PDF
PATENT WATCH India issues compulsory licence for sorafenib | Alnylam and Tekmira RNAi dispute escalates | Crestor injunctions prevent generics launch in Australia | Hedgehog signalling Charlotte Harrison p262 | doi:10.1038/nrd3719 PDF
AN AUDIENCE WITH Trevor Mundel p264 | doi:10.1038/nrd3720 Trevor Mundel, new President of Global Health at the Bill & Melinda Gates Foundation, discusses his plans for a high-throughput approach to translational research. PDF
FROM THE ANALYST'S COUCH Rare diseases and orphan drugs Irena Melnikova p267 | doi:10.1038/nrd3654 This article discusses market trends in the development of drugs for rare diseases, which have increasingly been recognized as providing attractive opportunities for the biopharmaceutical industry. PDF
FRESH FROM THE PIPELINE Aflibercept Michael W. Stewart, Seden Grippon & Peter Kirkpatrick p269 | doi:10.1038/nrd3700 Fusion protein that inhibits vascular endothelial growth factor signalling approved in the United States for the treatment of neovascular age-related macular degeneration. PDF
RESEARCH HIGHLIGHTS Top Neurodegenerative disease: RXR agonist reverses Alzheimer's disease p271 | doi:10.1038/nrd3706 PDF Neuromuscular disorders: Troponin activator improves muscle function p272 | doi:10.1038/nrd3703 PDF Stroke: Can PSD95 inhibitors widen the therapeutic window? p272 | doi:10.1038/nrd3716 PDF Metabolic disease: Identifying novel targets of resveratrol p273 | doi:10.1038/nrd3717 PDF Neurological disorders: A class of its own p274 | doi:10.1038/nrd3704 PDF IN BRIEF Neurological disorders: GM1 ganglioside improves motor function | Obesity and diabetes: Adenosine kinase inhibitor increases β-cells | Neurological disorders: Inhibiting tau oligomerization | Cancer: GSK3a is a new target in leukaemia PDF Drug Discovery JOBS of the week Professor in sociological alcohol and drug research Stockholm University Director Drug Development (m / w) Hays AG Scientist Drug Metabolism Pharmokinetics Otsuka Pharmaceutical Co., Ltd Postdoctoral Researcher in Drug Delivery The Ohio State University/Pharmaceutics/ Ainslie Lab Senior Drug Safety Analyst 1881 EMD Serono, Inc. More Science jobs from Drug Discovery EVENT Drug Resistance and Persistence in Tuberculosis (E1) 13.-18.05.12 Uganda More science events from
REVIEWS		Top
Novel molecular targets for atrial fibrillation therapy Dobromir Dobrev, Leif Carlsson & Stanley Nattel p275 | doi:10.1038/nrd3682 New insights into the mechanisms underlying atrial fibrillation have identified promising new approaches to prevent the fundamental processes that lead to the generation of arrhythmia. Dobrev and colleagues discuss the rationale for developing new anti-atrial fibrillation drugs, the molecular and structural motifs that they target, and the results obtained in experimental and clinical studies. Abstract | Full Text | PDF
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain Bernard P. Roques, Marie-Claude Fournié-Zaluski & Michel Wurm p292 | doi:10.1038/nrd3673 Dual enkephalinase inhibitors and fatty acid amide hydrolase inhibitors increase the levels of endogenous opioids and cannabinoids, respectively. Although their antinociceptive effects have been known for over a decade, they have only recently entered early-stage clinical trials. This Review compares the effects of these two potential classes of novel analgesics and discusses opportunities for combination therapies. Abstract | Full Text | PDF
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond P. Mark Hogarth & Geoffrey A. Pietersz p311 | doi:10.1038/nrd2909 Antibody Fc receptors (FcRs) connect innate and adaptive immune responses, and present attractive targets for the treatment of inflammatory diseases, cancer and infection. In this Review, Hogarth and Pietersz review the unique opportunities and challenges presented by this receptor class, and discuss the various strategies to manipulate FcR function. Abstract | Full Text | PDF
Corrigendum: Targeting IAP proteins for therapeutic intervention in cancer Simone Fulda & Domagoj Vucic p331 | doi:10.1038/nrd3698 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2010 Journal Citation Report (Thomson Reuters, 2011)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.